The main objectives of the Administrative Core (Core A) are to develop overarching collaborative initiatives and to provide the necessary coordination and prioritization of the available resources among the participating Research Projects and Reagent/Service Core (Core B). Core A will provide a forum through which the Project Directors and Core Leaders communicate openly and regularly. Activities that Core A will be coordinating include monthly Project Directors'meetings, monthly research conferences, annual research retreat, annual reports to the Advisory Committee, preparation, submission, renewal and monitoring of research protocols (animal, human and biosafety), and communication with internal and external funding agencies regarding budgetary matters. In close consultation with the Advisory Committee, Core A will play a central role in assessing the progress and productivity of this Program, resolve potential barriers and ensure that the entire program and each of its components are on the right track. Through these activities, the Core will serve to ensure cost-effectiveness, enhance program integration, accelerate scientific productivity, and maximize translational output.

Public Health Relevance

The Administrative Core will play a central role in coordinating all the collaborative, administrative, budgetary, and compliance matters for this Program Project grant and in ensuring synergy. Integration and productivity. This will in turn contribute directly to the goals of this Program to understand the molecular tumorigenesis and discover novel therapies for bladder cancer.

Agency
National Institute of Health (NIH)
Type
Research Program Projects (P01)
Project #
5P01CA165980-02
Application #
8765243
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
Budget End
Support Year
2
Fiscal Year
2014
Total Cost
Indirect Cost
Name
New York University
Department
Type
DUNS #
City
New York
State
NY
Country
United States
Zip Code
10016
Zhang, Jingjie; Gao, Guangxun; Chen, Liang et al. (2014) Hydrogen peroxide/ATR-Chk2 activation mediates p53 protein stabilization and anti-cancer activity of cheliensisin A in human cancer cells. Oncotarget 5:841-52
Cao, Zipeng; Li, Xueyong; Li, Jingxia et al. (2014) X-linked inhibitor of apoptosis protein (XIAP) lacking RING domain localizes to the nuclear and promotes cancer cell anchorage-independent growth by targeting the E2F1/Cyclin E axis. Oncotarget 5:7126-37
Vieira, Neide; Deng, Fang-Ming; Liang, Feng-Xia et al. (2014) SNX31: a novel sorting nexin associated with the uroplakin-degrading multivesicular bodies in terminally differentiated urothelial cells. PLoS One 9:e99644
Zhang, Ruowen; Wang, Yulei; Li, Jingxia et al. (2014) The Chinese herb isolate yuanhuacine (YHL-14) induces G2/M arrest in human cancer cells by up-regulating p21 protein expression through an p53 protein-independent cascade. J Biol Chem 289:6394-403
Fang, Yong; Wang, Yihong; Wang, Yulei et al. (2014) A new tumour suppression mechanism by p27Kip1: EGFR down-regulation mediated by JNK/c-Jun pathway inhibition. Biochem J 463:383-92
Zhu, Junlan; Zhang, Jingjie; Huang, Haishan et al. (2014) Crucial role of c-Jun phosphorylation at Ser63/73 mediated by PHLPP protein degradation in the cheliensisin a inhibition of cell transformation. Cancer Prev Res (Phila) 7:1270-81
Madka, Venkateshwar; Mohammed, Altaf; Li, Qian et al. (2014) Chemoprevention of urothelial cell carcinoma growth and invasion by the dual COX-LOX inhibitor licofelone in UPII-SV40T transgenic mice. Cancer Prev Res (Phila) 7:708-16
Cao, Zipeng; Li, Xueyong; Li, Jingxia et al. (2014) SUMOylation of RhoGDI* is required for its repression of cyclin D1 expression and anchorage-independent growth of cancer cells. Mol Oncol 8:285-96
Huang, Haishan; Ma, Li; Li, Jingxia et al. (2014) NF-?B1 inhibits c-Myc protein degradation through suppression of FBW7 expression. Oncotarget 5:493-505
Gao, Guangxun; Chen, Liang; Li, Jingxia et al. (2014) Isorhapontigenin (ISO) inhibited cell transformation by inducing G0/G1 phase arrest via increasing MKP-1 mRNA Stability. Oncotarget 5:2664-77

Showing the most recent 10 out of 13 publications